申请人:Himmelsbach Frank
公开号:US20120302566A1
公开(公告)日:2012-11-29
The present invention relates to compounds defined by formula (I)
wherein the variables R
1
, R
2
, R
3
, m, and n are defined as in claim
1
, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
本发明涉及由公式(I)定义的化合物,其中变量R1、R2、R3、m和n如权利要求1中所定义,具有有价值的药理活性。特别地,这些化合物是GPR40受体的激活剂,因此适用于治疗和预防可以受该受体影响的疾病,如代谢性疾病,特别是2型糖尿病。